Dr. Christophe Van Vaeck joined Augustine Therapeutics as CFO in July 2021. He brings more than 20 years of operational and strategic experience from the Life Sciences financial community. Since the end of 2017, as CFO of several early stage Belgian biotechs, where he dedicates himself fully to organizing promising Life Sciences companies to be ready for the next phase of their development. Before that he managed 10 years of investments and successful exits for both early-stage VC and mature PE companies in the biotech, diagnostic, MedTech, and healthcare service sectors at Gimv.

Christophe held board positions at Multiplicom, Spinart, Almaviva Santé and others. During his time at KBC securities, he was actively involved in the successful initial public offerings and subsequent fundraisings of Galapagos, Devgen, Thrombogenics, and Ablynx. Christophe started his career at Bank Degroof in 2001, after obtaining a PhD in Molecular and Cellular Biology at KULeuven, Belgium.